What is the optimal therapy for childhood AML?

David M. Loeb, Robert J. Arceci

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

The use of intensive therapy overa brief period of time has produced dramatic improvements in outcome for pediatric patients with acute myelogenous leukemia (AML), as has been demonstrated in studies by the major cooperative groups in the United States and Europe. Still, despite high-intensity chemotherapy and bone marrow transplantation, only about half of the children diagnosed with AML are cured. Future improvements are unlikely to come from further increases in chemotherapy intensity. Alternative approaches, such as risk-directed therapy based on different prognostic criteria; differentiation therapy with all-trans-retinoic acid (ATRA, Vesanoid), arsenic trioxide (Trisenox), or azacytidine; and immunotherapy with monoclonal antibodies, tumor vaccines, or cytokines may lead to further advances.

Original languageEnglish (US)
Pages (from-to)1057-1066; discussion 1066, 1068-1070
JournalOncology (Williston Park, N.Y.)
Volume16
Issue number8
StatePublished - Aug 2002
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Loeb, D. M., & Arceci, R. J. (2002). What is the optimal therapy for childhood AML? Oncology (Williston Park, N.Y.), 16(8), 1057-1066; discussion 1066, 1068-1070.